Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MAGENTA THERAPEUTICS, INC.

(MGTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Magenta Therapeutics : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study in Q4

09/15/2021 | 09:15am EST


ę MT Newswires 2021
All news about MAGENTA THERAPEUTICS, INC.
11/08B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-1..
MT
11/04Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outper..
MT
11/04Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
BU
11/04Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Condi..
BU
11/04MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/04Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights - F..
PU
11/04Magenta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/04MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, ..
AQ
10/04MAGENTA THERAPEUTICS : Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
BU
10/04Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
CI
More news
Analyst Recommendations on MAGENTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -70,7 M - -
Net cash 2021 174 M - -
P/E ratio 2021 -4,30x
Yield 2021 -
Capitalization 321 M 321 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 73
Free-Float 91,9%
Chart MAGENTA THERAPEUTICS, INC.
Duration : Period :
Magenta Therapeutics, Inc. Technical Analysis Chart | MGTA | US55910K1088 | MarketScreener
Technical analysis trends MAGENTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,50 $
Average target price 13,17 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Jason Gardner President, Chief Executive Officer & Director
Stephen Frank Mahoney COO, CFO, Treasurer & Chief Accounting Officer
Alison Francis Lawton Chairman
Lisa M. Olson Chief Scientific Officer & Head-Research
David Nichols Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
MAGENTA THERAPEUTICS, INC.-28.19%321
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530